Výsledky vyhledávání - "Geoff R Oxnard"

Abstract P3-07-02: Identification of potential germline variants (GV) on tumor comprehensive genomic profiling (CGP) in patients with advanced breast cancer (BC): BRCA1/2 and beyond

Autor: Marni B Tierno, Kali C Dougherty, Erica Gornstein, Dean C Pavlick, Alexa Schrock, Geoff R Oxnard

Publikováno v: Cancer Research. 82:P3-07

Background Detection of pathogenic GVs in patients with BC has implications for both patients and their family members. Management options such as increased surveillance, chemoprevention, and surgical prophylaxis are available to GV carriers. Beyond

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45de406b0bb44b5cc30473bb0c968013
https://doi.org/10.1158/1538-7445.sabcs21-p3-07-02

Zobrazit plný text záznamu

Abstract 305: POLE-specific variant classification strategy is critical for identifying patients who may benefit from immunotherapy

Autor: Rachel B. Keller, James Haberberger, Tyler Janovitz, Alexa B. Schrock, Hanna Tukachinsky, Lei Zhong, Douglas A. Mata, Lyle V. Lopez, Zoe Fleischmann, Radwa Sharaf, Ethan S. Sokol, Garrett M. Frampton, Nimesh R. Patel, Douglas I. Lin, Geoff R. Oxnard, Erik A. Williams, Julia A. Elvin, Brennan Decker

Publikováno v: Cancer Research. 83:305-305

BACKGROUND: Pathogenic POLE exonuclease domain mutations (pPOLE) undermine mismatch error correction during DNA replication, causing somatic ultramutation and response to immunotherapy. We examined the pan-cancer landscape of POLE mutations and appli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::07ecd21ee7bb1db9fa238c6b5b187be6
https://doi.org/10.1158/1538-7445.am2023-305

Zobrazit plný text záznamu

Abstract 4581: Feasibility of an amplicon-based liquid biopsy for ALK and ROS1 fusions in advanced non-small cell lung cancer (NSCLC) patients

Publikováno v: Cancer Research. 78:4581-4581

INTRODUCTION Circulating tumor DNA (ctDNA) is a surrogate material for somatic mutation detection, such as EGFR, BRAF or KRAS mutations in NSCLC patients, however the applicability of this technique for ALK and ROS1 fusion detection is poorly describ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::16f2d32514b773b5f80df50d9fa713de
https://doi.org/10.1158/1538-7445.am2018-4581

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání